Register for our free email digests:
Myriad Genetics, Inc.
http://www.myriad.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Myriad Genetics, Inc.
Ruth Bader Ginsburg’s Impact On Pharma, From Patents To The First Amendment
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.
AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer
Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.
Decade In Review: Biopharma's Shifting Legal Landscape
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
Global Approvals Snapshot: October 2019
October’s approvals include the US FDA approval of Myriad’s myChoice CDx companion diagnostic for GlaxoSmithKline’s ovarian cancer drug and the approval or Medtronic’s Valiant Navion thoracic stent graft system in Japan.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Assurex Health
- Counsyl, Inc.
- Crescendo Bioscience
- Myriad Genetic Laboratories, Inc.
- Myriad Pharmaceuticals
- Myriad RBM
- Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG
- Rules Based Medicine
- Sividon Diagnostics